Pharmaceutical Composition for Treating Hair Loss and Benign Prostatic Hyperplasia

Abstract

The present invention is related to an orally administered pharmaceutical composition for the prevention of hair loss; having the effects of epilation, hair toning, and hair growth; and for the treatment of female hirsutism and benign prostatic hyperplasia. The composition of the present invention is non-steroidal and is advantageous in that it has no side effects such as lowering of sexual function, etc. shown in the conventional oral treatment agents of related diseases.

1 . A pharmaceutical composition for the prevention of hair loss; and having the effects of epilation, hair toning, and hair growth; and for the treatment of female hirsutism and benign prostatic hyperplasia, which comprises as an active ingredient 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid, or its pharmaceutically acceptable salt, hydrate, or solvate. 
   
   
       2 . The pharmaceutical composition of  claim 1 , wherein said active ingredient is a racemate or optical isomer of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid. 
   
   
       3 . The pharmaceutical composition of  claim 2 , wherein said active ingredient is 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid dihydrochloride. 
   
   
       4 . The pharmaceutical composition of  claim 3 , wherein said composition is for oral administration or local administration. 
   
   
       5 . The pharmaceutical composition of  claim 4 , wherein said composition is in the form of a tablet, a powder, a dried syrup, a chewable tablet, a granule, a chewing tablet, a capsule, a soft capsule, a pill, a drink, or a sublingual tablet. 
   
   
       6 . The pharmaceutical composition of  claim 4 , wherein said composition is administered orally once to three times a day in a dosage amount of 1 to 2,000 mg/day based on the amount of the effective component. 
   
   
       7 . The pharmaceutical composition of  claim 6 , wherein said composition is administered orally once to three times a day in a dosage amount of 5 to 300 mg/day based on the amount of the effective component.